These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17276177)

  • 1. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
    El Harchaoui K; van der Steeg WA; Stroes ES; Kuivenhoven JA; Otvos JD; Wareham NJ; Hutten BA; Kastelein JJ; Khaw KT; Boekholdt SM
    J Am Coll Cardiol; 2007 Feb; 49(5):547-53. PubMed ID: 17276177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
    van Capelleveen JC; Bernelot Moens SJ; Yang X; Kastelein JJP; Wareham NJ; Zwinderman AH; Stroes ESG; Witztum JL; Hovingh GK; Khaw KT; Boekholdt SM; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1206-1212. PubMed ID: 28473441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-density lipoprotein particle size and concentration and coronary risk.
    El Harchaoui K; Arsenault BJ; Franssen R; Després JP; Hovingh GK; Stroes ES; Otvos JD; Wareham NJ; Kastelein JJ; Khaw KT; Boekholdt SM
    Ann Intern Med; 2009 Jan; 150(2):84-93. PubMed ID: 19153411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.
    Meuwese MC; Stroes ES; Hazen SL; van Miert JN; Kuivenhoven JA; Schaub RG; Wareham NJ; Luben R; Kastelein JJ; Khaw KT; Boekholdt SM
    J Am Coll Cardiol; 2007 Jul; 50(2):159-65. PubMed ID: 17616301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
    van der Steeg WA; Boekholdt SM; Stein EA; El-Harchaoui K; Stroes ES; Sandhu MS; Wareham NJ; Jukema JW; Luben R; Zwinderman AH; Kastelein JJ; Khaw KT
    Ann Intern Med; 2007 May; 146(9):640-8. PubMed ID: 17470832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study.
    Rip J; Nierman MC; Wareham NJ; Luben R; Bingham SA; Day NE; van Miert JN; Hutten BA; Kastelein JJ; Kuivenhoven JA; Khaw KT; Boekholdt SM
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):637-42. PubMed ID: 16373616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue factor serum levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.
    Keller TT; Choi D; Nagel C; Te Velthuis H; Gerdes VE; Wareham NJ; Bingham SA; Luben R; Hack CE; Reitsma PH; Levi M; Khaw KT; Boekholdt SM
    J Thromb Haemost; 2006 Nov; 4(11):2391-6. PubMed ID: 16938131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
    van der Steeg WA; Holme I; Boekholdt SM; Larsen ML; Lindahl C; Stroes ES; Tikkanen MJ; Wareham NJ; Faergeman O; Olsson AG; Pedersen TR; Khaw KT; Kastelein JJ
    J Am Coll Cardiol; 2008 Feb; 51(6):634-42. PubMed ID: 18261682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.
    Gardner CD; Fortmann SP; Krauss RM
    JAMA; 1996 Sep; 276(11):875-81. PubMed ID: 8782636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease.
    Birjmohun RS; Dallinga-Thie GM; Kuivenhoven JA; Stroes ES; Otvos JD; Wareham NJ; Luben R; Kastelein JJ; Khaw KT; Boekholdt SM
    Circulation; 2007 Oct; 116(18):2029-35. PubMed ID: 17923573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.
    Boekholdt SM; Kuivenhoven JA; Wareham NJ; Peters RJ; Jukema JW; Luben R; Bingham SA; Day NE; Kastelein JJ; Khaw KT
    Circulation; 2004 Sep; 110(11):1418-23. PubMed ID: 15337694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
    Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
    Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein particle profiles compared with standard lipids in association with coronary artery calcification in the general Japanese population.
    Hisamatsu T; Fujiyoshi A; Miura K; Ohkubo T; Kadota A; Kadowaki S; Kadowaki T; Yamamoto T; Miyagawa N; Zaid M; Torii S; Takashima N; Murakami Y; Okamura T; Horie M; Ueshima H;
    Atherosclerosis; 2014 Oct; 236(2):237-43. PubMed ID: 25105580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smaller low-density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients: associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with low-density lipoprotein size.
    Kimura H; Miyazaki R; Imura T; Masunaga S; Shimada A; Mikami D; Kasuno K; Takahashi N; Hirano T; Yoshida H
    Nephrology (Carlton); 2011 Aug; 16(6):558-66. PubMed ID: 21352420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.
    Soedamah-Muthu SS; Chang YF; Otvos J; Evans RW; Orchard TJ;
    Diabetologia; 2003 May; 46(5):674-82. PubMed ID: 12743701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.
    Rosenson RS; Otvos JD; Freedman DS
    Am J Cardiol; 2002 Jul; 90(2):89-94. PubMed ID: 12106834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma oxidized low-density lipoprotein is an independent risk factor in young patients with coronary artery disease.
    Huang Y; Hu Y; Mai W; Cai X; Song Y; Wu Y; Dong Y; Huang H; He Z; Li W; Yang Y; Rao S
    Dis Markers; 2011; 31(5):295-301. PubMed ID: 22048271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women.
    Blake GJ; Otvos JD; Rifai N; Ridker PM
    Circulation; 2002 Oct; 106(15):1930-7. PubMed ID: 12370215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum high-density lipoprotein-cholesterol levels modify the association between plasma levels of oxidatively modified low-density lipoprotein and coronary artery disease in men.
    Zhang B; Bai H; Liu R; Kumagai K; Itabe H; Takano T; Saku K
    Metabolism; 2004 Apr; 53(4):423-9. PubMed ID: 15045686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.